

Markus Eckstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/199887/publications.pdf>

Version: 2024-02-01

107
papers

1,981
citations

361413

20
h-index

377865

34
g-index

112
all docs

112
docs citations

112
times ranked

2231
citing authors

#	ARTICLE	IF	CITATIONS
1	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. <i>Cancer Immunology Research</i> , 2019, 7, 923-938.	3.4	148
2	Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides. <i>European Urology</i> , 2020, 78, 256-264.	1.9	96
3	PD-L1 assessment in urothelial carcinoma: a practical approach. <i>Annals of Translational Medicine</i> , 2019, 7, 690-690.	1.7	77
4	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. <i>European Journal of Cancer</i> , 2019, 106, 234-243.	2.8	75
5	In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 267-274.	2.8	58
6	EMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells. <i>Cell Death and Disease</i> , 2020, 11, 147.	6.3	58
7	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?â€¦. <i>European Urology</i> , 2020, 78, 682-687.	1.9	57
8	High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 403-412.	4.2	54
9	Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. , 2020, 8, e001378.		51
10	Deep learning for diagnosis and survival prediction in soft tissue sarcoma. <i>Annals of Oncology</i> , 2021, 32, 1178-1187.	1.2	51
11	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. , 2020, 8, e000162.		45
12	Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. , 2021, 9, e001845.		36
13	mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3396.	4.1	35
14	Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. <i>Histopathology</i> , 2019, 75, 865-875.	2.9	35
15	MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. <i>Nature Communications</i> , 2021, 12, 5066.	12.8	34
16	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. <i>Oncotarget</i> , 2018, 9, 15001-15014.	1.8	33
17	CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. <i>Scientific Reports</i> , 2018, 8, 14383.	3.3	32
18	ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. <i>Urologia Internationalis</i> , 2017, 98, 282-289.	1.3	30

#	ARTICLE	IF	CITATIONS
19	Generation and characterization of hepatocellular carcinoma cell lines with enhanced cancer stem cell potential. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 6238-6248.	3.6	27
20	Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>in Situ</i> Driven by Key Signaling Pathways Including ECM Remodeling. <i>Cancer Research</i> , 2021, 81, 1552-1566.	0.9	26
21	Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. <i>BMC Cancer</i> , 2020, 20, 230.	2.6	24
22	Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. <i>European Journal of Cancer</i> , 2020, 140, 55-62.	2.8	23
23	Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. , 2022, 10, e003747.		23
24	High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. <i>Translational Oncology</i> , 2017, 10, 340-345.	3.7	22
25	Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening. <i>Oncotarget</i> , 2018, 9, 25935-25945.	1.8	22
26	Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype. <i>Cancers</i> , 2020, 12, 763.	3.7	22
27	Risk factors associated with positive surgical margins™ location at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , 2021, 39, 4363-4371.	2.2	22
28	Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. <i>World Journal of Urology</i> , 2021, 39, 4011-4019.	2.2	22
29	<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. , 2021, 9, e002949.		22
30	CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage. <i>Cancers</i> , 2020, 12, 1253.	3.7	21
31	Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. <i>Cancers</i> , 2021, 13, 1424.	3.7	21
32	Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer. <i>Translational Oncology</i> , 2018, 11, 467-476.	3.7	19
33	<i>FOXM1</i> overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage <i>pT1</i> non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019, 123, 187-196.	2.5	19
34	Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer. <i>International Journal of Urology</i> , 2018, 25, 442-449.	1.0	17
35	Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients. <i>Scientific Reports</i> , 2018, 8, 17693.	3.3	17
36	Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis. <i>Cancers</i> , 2020, 12, 2794.	3.7	17

#	ARTICLE	IF	CITATIONS
37	Same same but different: A Web-based deep learning application revealed classifying features for the histopathologic distinction of cortical malformations. <i>Epilepsia</i> , 2020, 61, 421-432.	5.1	17
38	High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 248-256.e2.	1.9	16
39	Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer. <i>European Urology</i> , 2018, 74, 527-529.	1.9	16
40	Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. <i>Translational Oncology</i> , 2019, 12, 661-668.	3.7	16
41	PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. <i>Current Drug Targets</i> , 2021, 22, 162-170.	2.1	16
42	Endogenous Retroviral K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 657187.	2.8	16
43	FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. <i>Oncotarget</i> , 2017, 8, 47595-47606.	1.8	16
44	Extramedullary plasmacytoma: Tumor occurrence and therapeutic concepts – A follow-up. <i>Cancer Medicine</i> , 2022, 11, 4743-4755.	2.8	16
45	Gpr126 (Adgrg6) is expressed in cell types known to be exposed to mechanical stimuli. <i>Annals of the New York Academy of Sciences</i> , 2019, 1456, 96-108.	3.8	15
46	ANLN and TLE2 in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data. <i>Cancers</i> , 2019, 11, 1840.	3.7	15
47	C-reactive protein flare response predicts long-term efficacy to first-line anti-PD-1 based combination therapy in metastatic renal cell carcinoma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1358.	3.8	15
48	C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. <i>European Journal of Cancer</i> , 2022, 167, 13-22.	2.8	15
49	Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. <i>Future Oncology</i> , 2019, 15, 2199-2202.	2.4	14
50	High Stroma T-Cell Infiltration is Associated with Better Survival in Stage pT1 Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8407.	4.1	14
51	FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy. <i>Journal of Clinical Medicine</i> , 2020, 9, 994.	2.4	14
52	New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?. <i>Annals of Translational Medicine</i> , 2019, 7, S135-S135.	1.7	13
53	Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays. <i>Laboratory Investigation</i> , 2019, 99, 1527-1534.	3.7	13
54	Intraoperative free margins assessment of oropharyngeal squamous cell carcinoma with confocal laser endomicroscopy: a pilot study. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 4433-4439.	1.6	12

#	ARTICLE	IF	CITATIONS
55	Feasibility of intraoperative assessment of safe surgical margins during laryngectomy with confocal laser endomicroscopy: A pilot study. <i>Auris Nasus Larynx</i> , 2021, 48, 764-769.	1.2	12
56	The effects of an overnight holding of whole blood at room temperature on haemoglobin modification and <i>in vitro</i> markers of red blood cell aging. <i>Vox Sanguinis</i> , 2015, 108, 359-367.	1.5	11
57	Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 288.	8.6	11
58	Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 1959.	3.7	11
59	IQGAP3, a YAP Target, Is Required for Proper Cell-Cycle Progression and Genome Stability. <i>Molecular Cancer Research</i> , 2021, 19, 1712-1726.	3.4	11
60	TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers. <i>Genes</i> , 2021, 12, 230.	2.4	10
61	The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 6567-6578.	1.9	10
62	Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients. <i>Cancers</i> , 2019, 11, 2029.	3.7	9
63	Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 539-544.	3.1	9
64	Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas. <i>Modern Pathology</i> , 2020, 33, 1433-1442.	5.5	9
65	POFUT1 mRNA expression as an independent prognostic parameter in muscle-invasive bladder cancer. <i>Translational Oncology</i> , 2021, 14, 100900.	3.7	9
66	Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. <i>BMC Cancer</i> , 2021, 21, 314.	2.6	9
67	Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer. <i>Scientific Reports</i> , 2021, 11, 17981.	3.3	9
68	Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 734872.	2.8	9
69	Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e629-e642.	1.9	8
70	Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. <i>Cancers</i> , 2021, 13, 2327.	3.7	8
71	Systematic classification of confocal laser endomicroscopy for the diagnosis of oral cavity carcinoma. <i>Oral Oncology</i> , 2022, 132, 105978.	1.5	8
72	DICER1 mutation-positive giant botryoid fibroepithelial polyp of the urinary bladder mimicking embryonal rhabdomyosarcoma. <i>Human Pathology</i> , 2019, 84, 1-7.	2.0	7

#	ARTICLE	IF	CITATIONS
73	Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7890-7900.	3.6	7
74	Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. <i>Journal of Clinical Pathology</i> , 2023, 76, 126-132.	2.0	7
75	Neoadjuvant concurrent chemoradiotherapy with and without hyperthermia in retroperitoneal sarcomas: feasibility, efficacy, toxicity, and long-term outcome. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1063-1071.	2.0	7
76	The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 811200.	4.8	7
77	Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 528-528.	1.6	7
78	Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 272-294.	0.1	6
79	Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy. <i>Cells</i> , 2021, 10, 159.	4.1	6
80	Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. <i>Urology</i> , 2021, 157, 93-101.	1.0	6
81	Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 63.e19-63.e26.	1.6	6
82	PD1/PD-L1 Axis in Uro-oncology. <i>Current Drug Targets</i> , 2020, 21, 1293-1300.	2.1	6
83	Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy. <i>European Urology</i> , 2022, 81, 606-614.	1.9	6
84	Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients. <i>Cancers</i> , 2020, 12, 2639.	3.7	5
85	KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 473.	2.5	5
86	Impact of intraepithelial capillary loops and atypical vessels in confocal laser endomicroscopy for the diagnosis of laryngeal and hypopharyngeal squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 2029-2037.	1.6	5
87	High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 63.e9-63.e18.	1.6	5
88	Systematic interpretation of confocal laser endomicroscopy: larynx and pharynx confocal imaging score. <i>Acta Otorhinolaryngologica Italica</i> , 2022, 42, 26-33.	1.5	5
89	Novel Criteria for Intratumoral Budding with Prognostic Relevance for Colon Cancer and Its Histological Subtypes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13108.	4.1	5
90	Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 530.e19-530.e27.	1.6	4

#	ARTICLE	IF	CITATIONS
91	Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC). Pathology and Oncology Research, 2020, 26, 1625-1632.	1.9	4
92	Brain and Breast Cancer Cells with PTEN Loss of Function Reveal Enhanced Durotaxis and RHOB Dependent Amoeboid Migration Utilizing 3D Scaffolds and Aligned Microfiber Tracts. Cancers, 2021, 13, 5144.	3.7	4
93	Validity of tissue homogeneity in confocal laser endomicroscopy on the diagnosis of laryngeal and hypopharyngeal squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2022, 279, 4147-4156.	1.6	4
94	High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. Life, 2021, 11, 642.	2.4	3
95	Validation of a classification and scoring system for the diagnosis of laryngeal and pharyngeal squamous cell carcinomas by confocal laser endomicroscopy. Brazilian Journal of Otorhinolaryngology, 2022, 88, S26-S32.	1.0	3
96	Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients. Cells, 2021, 10, 1796.	4.1	3
97	A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).. Journal of Clinical Oncology, 2020, 38, 6519-6519.	1.6	3
98	Fast whole-slide cartography in colon cancer histology using superpixels and CNN classification. Journal of Medical Imaging, 2022, 9, 027501.	1.5	3
99	Acute systemic knockdown of <i>Atg7</i> is lethal and causes pancreatic destruction in shRNA transgenic mice. Autophagy, 2022, 18, 2880-2893.	9.1	3
100	F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial. Annals of Nuclear Medicine, 2022, 36, 623-633.	2.2	3
101	Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial). Annals of Oncology, 2019, 30, v456-v457.	1.2	2
102	Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40. European Urology, 2019, 75, e162-e163.	1.9	2
103	Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial.. Journal of Clinical Oncology, 2022, 40, 6064-6064.	1.6	2
104	Imaging, histopathological degree of degeneration and clinical findings – Do these correlate in patients with temporomandibular joint disorders. Journal of Stomatology, Oral and Maxillofacial Surgery, 2022, 123, 353-357.	1.3	1
105	Reduction of Elective Radiotherapy Treatment Volume in Definitive Treatment of Locally Advanced Head and Neck Cancer – Comparison of a Prospective Trial with a Revised Simulated Contouring Approach. Journal of Clinical Medicine, 2021, 10, 4653.	2.4	1
106	Hrd in ovarian cancer: Defined today, evolving for the future.. Journal of Clinical Oncology, 2020, 38, e18052-e18052.	1.6	1
107	Prognostic Role of mRNA-Expression of Aquaporins (AQP) 3, 4, 7 and 9 in Stage pT1 Non-Muscle-Invasive Bladder Cancer. Bladder Cancer, 2021, 7, 71-78.	0.4	0